CARsgen therapeutics buys back 1.02m shares, driving up treasury stock

CARsgen Therapeutics Holdings Limited reported a repurchase of 1,020,000 ordinary shares on December 11, 2025. This transaction reduced the number of issued shares (excluding treasury shares) by 1,020,000 to 573,049,155, representing 0.18% of the existing number of issued shares before the event. Concurrently, the number of treasury shares increased by 1,020,000, bringing the total treasury shares to 4,924,000.

The shares were repurchased on the Exchange at prices ranging from HKD 15.06 to HKD 15.91, with an average price of HKD 15.5747 per share. The aggregate price paid for these repurchases amounted to HKD 15,886,194. This repurchase activity aligns with the company's mandate granted on May 22, 2025, which authorized the repurchase of up to 57,543,590 shares.

As of December 11, 2025, a total of 5,379,000 shares have been repurchased under this mandate, representing 0.935% of the issued shares (excluding treasury shares) at the time the mandate was granted. The moratorium period for any new share issues or sales/transfers of treasury shares after this repurchase extends until January 10, 2026.